Skip to main content
. Author manuscript; available in PMC: 2009 Jun 29.
Published in final edited form as: J Dermatol Sci. 2007 Aug 8;48(2):87–101. doi: 10.1016/j.jdermsci.2007.06.006

Figure 5. Expression and kinetic profile highlighting temporal reductions in density of CD14+, CD83+, and CD86+ cells in psoriatic patients before and after treatment with adalimumab.

Figure 5

Figure 5

Untreated PP skin (PP day 0) is characterized by an increased number of mononuclear cells expressing CD14+ compared to PN skin (a and f), as well as increased number of DCs expressing maturation markers CD83 (g and l) and CD86 (m and r). Beneath each representative staining profile of untreated and treated PP skin and PN skin are panels depicting individual data points for each of the six treated subjects (left side), as well as a summary panel depicting mean +/− SEM for the group (n=6). The reduction in these markers initially became statistically significant at day 7 (asterisk; p<0.05 comparing untreated to treated samples).